Cynata Therapeutics is an ASX-listed (ASX:CYP) clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™. A successful world-first clinical trial in graft-versus-host disease has been completed, meeting all safety and efficacy endpoints. A Phase 3 clinical trial in osteoarthritis and a Phase 2 clinical trial in respiratory distress (eg from COVID-19) commenced in 2020. The Company’s major shareholders include Fidelity, one of the world’s largest investment houses, BioScience Managers, a leading global healthcare institutional investor, and Fujifilm. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor-derived mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve consistent, economic manufacture at a commercial scale.
- Business Directory